Oxford BioMedica Plc - Company Profile
Powered by 
All the sales intelligence you need on Oxford BioMedica Plc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Oxford BioMedica Plc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Oxford BioMedica Plc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Oxford Biomedica plc (OXB) provides process development and manufacturing services tailored to pharmaceutical and biotech companies in the cell and gene therapy sector. The company specialises in viral vector manufacturing, including lentiviral, AAV, and adenoviral vectors. Notable brands associated with OXB include the Lentivector platform, inAAVate, and AdenoVate. OXB's products and services are utilised by clients in the pharmaceutical and biotechnology industries to develop and scale cell and gene therapy products across various therapeutic areas. Based on this platform, it has a partnership and license agreement with other companies to develop potential gene and cell therapy products. OXB operates globally, targeting markets in the cell and gene therapy sector. The company has a presence in different locations in the UK and in Boston, the US. The company is headquartered in Oxford, England, the UK.
Headquarters
United Kingdom
Address
Windrush Court, Transport Way, Oxford, England, OX46LT
Website
www.oxb.com
Telephone
44 1865 783000
No of Employees
986
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
OXB (LON)
Revenue (2024)
$222.3M
31%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
30.2%
(2024 vs 2023)
Market Cap*
$1.0B
Net Profit Margin (2024)
XYZ
46.8%
(2024 vs 2023)
* As of and is in US$
Oxford BioMedica Plc premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Approved: | CDMO | Kymriah |
| Kymriah- Relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia (ALL) | LentiVector | |
| Pipeline | TetraVecta | |
| XYZ | ||
| XYZ | ||
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | New Products/Services | In April, the company launched a fast-track GMP manufacturing service for lentiviral and adeno-associated viral vectors. |
| 2026 | Contracts/Agreements | In March, the company entered into a licensing and option agreement with VVMF to grant non-exclusive rights to its inAAVate platform. |
| 2026 | Contracts/Agreements | In February, the company signed a multi-year commercial supply agreement with Bristol-Myers Squibb to manufacture lentiviral vectors for its CAR-T programs. |
Competitor Comparison
| Key Parameters | Oxford BioMedica Plc | Lonza Group Ltd | Almac Group Ltd | Genetix Biotherapeutics Inc | Autolus Therapeutics Plc |
|---|---|---|---|---|---|
| Headquarters | United Kingdom | Switzerland | United Kingdom | United States of America | United Kingdom |
| City | Oxford | Basel | Craigavon | Somerville | London |
| State/Province | England | Basel-Stadt | Northern Ireland | Massachusetts | England |
| No. of Employees | 986 | 16,866 | 7,800 | 248 | 754 |
| Entity Type | Public | Public | Private | Private | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Frederic Roch Doliveux | Chairman | Executive Board | 2020 | 70 |
| Peter Georg Soelkner | Vice Chairman | Executive Board | 2024 | 60 |
| Frank Mathias | Chief Executive Officer; Director | Executive Board | 2023 | 64 |
| Lucinda (Lucy) Crabtree | Director; Chief Financial Officer | Executive Board | 2024 | 47 |
| Lisa Doman | Chief People Officer | Senior Management | 2022 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer